Physician profile
Marcus Cox
NPI 1922298868
$48,089.22
in general payments reported to CMS, 2019-2025
45 companies · $1,110 in 2025
The $1,110 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $35K · 2020: $7,084 · 2021: $1,067 · 2022: $831 · 2023: $1,137 · 2024: $1,463 · 2025: $1,110.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,612 · Education: $98.10.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,612.05 |
| Education | $98.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $40,968.18 | 2019-2021 | |
| Amgen INC. | $862.57 | 2019-2025 | Repatha, Repatha |
| Janssen Pharmaceuticals, INC | $751.80 | 2019-2024 | Xarelto |
| Abbott Laboratories | $505.46 | 2021-2025 | Dragonfly Opstar, Triclip, Esprit |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $441.73 | 2019-2025 | Lifevest |
| Astrazeneca Pharmaceuticals Lp | $367.27 | 2020-2024 | Farxiga, Wainua |
| Sanofi-Aventis U.S. LLC | $354.00 | 2019-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $266.18 | 2020-2025 | Jardiance |
| Cvrx, INC. | $262.24 | 2021-2025 | Barostim Neo System |
| Allergan, INC. | $229.34 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $197.02 | 2019-2024 | Camzyos, Eliquis |
| Esperion Therapeutics, INC. | $195.50 | 2020-2025 | Nexletol |
| Novo Nordisk INC | $191.06 | 2021-2024 | Ozempic, Rybelsus, Wegovy |
| Abiomed | $184.60 | 2023 | Impella |
| Kiniksa Pharmaceuticals International, Plc | $183.39 | 2024 | Arcalyst |
Show all 45 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $179.29 | 2019-2025 | Watchman Flx |
| Novartis Pharmaceuticals Corporation | $143.23 | 2019-2025 | |
| Alnylam Pharmaceuticals INC. | $141.25 | 2021-2025 | Amvuttra |
| Scpharmaceuticals INC. | $134.06 | 2024-2025 | |
| Pfizer INC. | $125.10 | 2019-2022 | |
| Actelion Pharmaceuticals US, INC. | $124.92 | 2019-2025 | Uptravi, Opsumit, Opsynvi |
| Regeneron Healthcare Solutions, INC. | $105.44 | 2019-2024 | Evkeeza |
| Bayer Healthcare Pharmaceuticals INC. | $100.66 | 2021-2025 | |
| W. L. Gore & Associates, INC. | $98.10 | 2023 | Gore Cardioform Septal Occluder |
| Merck Sharp & Dohme LLC | $94.30 | 2021-2023 | Verquvo |
| Baxter Healthcare | $92.38 | 2023-2025 | Hillrom - Carnation Ambulatory Monitor, Hillrom - Cardiac Ambulatory Monitor |
| Inari Medical, INC. | $85.40 | 2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Biotronik INC. | $75.79 | 2021 | |
| Philips North America LLC | $71.20 | 2024 | (Ck4) Mcot, (Ck7) Extended Holter |
| Kiniksa Pharmaceuticals, Ltd. | $68.95 | 2022-2023 | Arcalyst |
| Lexicon Pharmaceuticals, INC. | $55.68 | 2023-2024 | Inpefa |
| Lilly USA, LLC | $45.50 | 2024 | Zepbound |
| Gilead Sciences, INC. | $45.00 | 2019 | |
| Shockwave Medical, INC | $44.59 | 2024-2025 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Genzyme Corporation | $42.22 | 2021-2024 | |
| Arbor Pharmaceuticals, INC. | $40.67 | 2019-2021 | |
| Conmed Corporation | $40.60 | 2023 | Visiclear, Airseal |
| Impulse Dynamics (USA) INC. | $40.12 | 2023 | Optimizer |
| Kowa Pharmaceuticals America, INC. | $31.19 | 2019-2021 | |
| Bridgebio Pharma, INC. | $21.12 | 2025 | Attruby |
| Medtronic, INC. | $18.91 | 2023 | Linq II |
| Zoll Respicardia, INC. | $18.84 | 2024 | Remede System |
| Daiichi Sankyo INC. | $16.50 | 2021 | |
| Kestra Medical Technology Services, INC. | $15.87 | 2025 | Assure Wcd |
| Bardy Diagnostics, INC. | $12.00 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marcus Cox listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.